The Claim
In adults with type 2 diabetes, once-weekly exenatide does not significantly reduce the risk of a composite renal outcome consisting of a 40% decline in eGFR, initiation of renal replacement therapy, or renal death when analyzed without statistical adjustment; however, a modest reduction in a broader composite renal outcome that additionally includes macroalbuminuria was observed following statistical adjustment.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly diabetes shot called exenatide doesn’t seem to lower the risk of serious kidney problems in adults with type 2 diabetes when looking at the raw data. But when researchers adjusted the numbers, it showed a small benefit when including a wider range of kidney issues, like high protein in the urine.
See the scientific wording
Once-weekly exenatide does not reduce the risk of a composite renal outcome including 40% eGFR decline, renal replacement, or renal death in adults with type 2 diabetes when analyzed without adjustment, though a modest reduction in a broader composite including macroalbuminuria was observed after statistical adjustment.
What the research says
1 studyThe study looked at a weekly diabetes shot called exenatide and found it didn’t clearly protect kidneys unless they used special number adjustments, which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.